Acacia Research (ACTG), Biomet Enter Patent Settlement, License
Get Alerts ACTG Hot Sheet
Price: $4.38 +0.46%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.5%
EPS Growth %: -900.0%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 7.5%
EPS Growth %: -900.0%
Join SI Premium – FREE
Acacia Research Corporation (Nasdaq: ACTG) announced today that its Bonutti Skeletal Innovations LLC subsidiary has entered into a settlement and patent license agreement with Biomet, Inc., Biomet Sports Medicine, LLC, Biomet Manufacturing, LLC (formerly doing business as Biomet Manufacturing Corp.) The agreement resolves litigation pertaining to suture anchors and platelet concentration that was pending in the United States District Court for the Northern District of Indiana.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Optimi Health names Dr. Michael Blough as chief clinical officer
- Garg Group claims 46% shareholder backing in Better board fight
- SEALSQ and WISeKey expand quantum infrastructure across five countries
Create E-mail Alert Related Categories
Corporate News, Life EnjoyedSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share